Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

How tumours escape mass destruction

Abstract

It is now well established that the immune system can control neoplastic development and growth in a process termed immunosurveillance. A link between host immunosurveillance and neoplastic progression is revealed in cases where the immune response becomes compromised due to genetic or other pathological conditions, resulting in a substantially increased incidence and rate of spontaneous tumour formation in both preclinical animal models and patients. It has also been demonstrated in tumour-bearing hosts that the tumorigenic process itself can promote a state of immunosuppression that, in turn, facilitates neoplastic progression. The ability of neoplastic populations to induce a hostile microenvironment through both cell contact-dependent and -independent immunosuppressive networks is a significant barrier to effective cell-mediated immunity and immunotherapy. Thus, a competent immune system is integral for the control of neoplastic disease, and dissecting the plethora of tumour escape mechanisms that disrupt this essential host defense capability is integral for the development of effective immunotherapeutic paradigms.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Abrams SI . (2004). Role of anti-CTLA-4 therapies in the treatment of cancer. Curr Opin Mol Ther 6: 71–77.

    CAS  PubMed  Google Scholar 

  • Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678–689.

    CAS  PubMed  Google Scholar 

  • Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P et al. (2002). Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195: 1303–1316.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Blank C, Mackensen A . (2007). Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56: 739–745.

    PubMed  Google Scholar 

  • Bosque A, Pardo J, Martinez-Lorenzo MJ, Lasierra P, Larrad L, Marzo I et al. (2005). Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL. Eur J Immunol 35: 1812–1821.

    CAS  PubMed  Google Scholar 

  • Bron LP, Scolyer RA, Thompson JF, Hersey P . (2004). Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma. Pathology 36: 561–565.

    CAS  PubMed  Google Scholar 

  • Bronte V, Zanovello P . (2005). Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641–654.

    Article  CAS  PubMed  Google Scholar 

  • Bui JD, Schreiber RD . (2007). Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19: 203–208.

    CAS  PubMed  Google Scholar 

  • Chang CC, Ferrone S . (2007). Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56: 227–236.

    CAS  PubMed  Google Scholar 

  • Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L et al. (2003). Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res 63: 9007–9015.

    CAS  PubMed  Google Scholar 

  • Curiel TJ . (2007). Tregs and rethinking cancer immunotherapy. J Clin Invest 117: 1167–1174.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942–949.

    CAS  PubMed  Google Scholar 

  • Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP et al. (2005). Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11: 728–734.

    CAS  PubMed  Google Scholar 

  • Dudley ME, Rosenberg SA . (2003). Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666–675.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850–854.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dunn GP, Koebel CM, Schreiber RD . (2006). Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836–848.

    CAS  PubMed  Google Scholar 

  • Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP et al. (2005). Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201: 1591–1602.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Espana L, Fernandez Y, Rubio N, Torregrosa A, Blanco J, Sierra A . (2004). Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res Treat 87: 33–44.

    CAS  PubMed  Google Scholar 

  • Ferris RL, Whiteside TL, Ferrone S . (2006). Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12: 3890–3895.

    CAS  PubMed  Google Scholar 

  • Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25: 2546–2553.

    CAS  PubMed  Google Scholar 

  • Flies DB, Chen L . (2007). The new B7s: playing a pivotal role in tumor immunity. J Immunother (1997) 30: 251–260.

    CAS  Google Scholar 

  • Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027–1034.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee JH et al. (2007). Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 13: 4840–4848.

    CAS  PubMed  Google Scholar 

  • Gallimore A, Sakaguchi S . (2002). Regulation of tumour immunity by CD25+ T cells. Immunology 107: 5–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y et al. (1999). A ‘stealth effect’: adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 163: 4886–4893.

    CAS  PubMed  Google Scholar 

  • Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF et al. (2005). Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27: 611–615.

    PubMed  Google Scholar 

  • Greeneltch K, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K et al. (2007). Host immunosurveillance controls tumor growth via IRF-8-dependent mechanisms. Cancer Res 67: 10406–10416.

    CAS  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.

    CAS  PubMed  Google Scholar 

  • Harizi H, Juzan M, Grosset C, Rashedi M, Gualde N . (2001). Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol 209: 19–28.

    CAS  PubMed  Google Scholar 

  • Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M et al. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089–1096.

    CAS  PubMed  Google Scholar 

  • Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT et al. (2002). Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8: 2553–2562.

    PubMed  Google Scholar 

  • Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F et al. (1996). Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87: 307–317.

    CAS  PubMed  Google Scholar 

  • Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H . (2003). Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404–4408.

    PubMed  Google Scholar 

  • Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293–12297.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Jung YJ, Kim JY, Park JH . (2004). TGF-beta1 inhibits Fas-mediated apoptosis by regulating surface Fas and cFLIPL expression in human leukaemia/lymphoma cells. Int J Mol Med 13: 99–104.

    CAS  PubMed  Google Scholar 

  • Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S . (1996). Fas expression and function in normal and malignant breast cell lines. Cancer Res 56: 4791–4798.

    CAS  PubMed  Google Scholar 

  • Kim R, Emi M, Tanabe K, Uchida Y, Toge T . (2004). The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100: 2281–2291.

    CAS  PubMed  Google Scholar 

  • Koneru M, Schaer D, Monu N, Ayala A, Frey AB . (2005). Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function. J Immunol 174: 1830–1840.

    CAS  PubMed  Google Scholar 

  • Korman AJ, Peggs KS, Allison JP . (2006). Checkpoint blockade in cancer immunotherapy. Adv Immunol 90: 297–339.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314–1321.

    CAS  PubMed  Google Scholar 

  • Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM et al. (2006). B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103: 10391–10396.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Krammer PH, Galle PR, Moller P, Debatin KM . (1998). CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res 75: 251–273.

    CAS  PubMed  Google Scholar 

  • Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al. (2006). B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203: 871–881.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kusmartsev S, Gabrilovich DI . (2006). Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55: 237–245.

    PubMed  Google Scholar 

  • Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL . (2004). Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 3755–3762.

    CAS  PubMed  Google Scholar 

  • Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I et al. (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261–268.

    CAS  PubMed  Google Scholar 

  • Leach DR, Krummel MF, Allison JP . (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734–1736.

    CAS  PubMed  Google Scholar 

  • Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS et al. (1999). Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5: 677–685.

    CAS  PubMed  Google Scholar 

  • Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA . (2006). Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99–146.

    CAS  PubMed  Google Scholar 

  • Lin EY, Pollard JW . (2007). Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67: 5064–5066.

    CAS  PubMed  Google Scholar 

  • Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C . (2007). The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110: 3192–3201.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Liu K, Abrams SI . (2003a). Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol 170: 5973–5980.

    CAS  PubMed  Google Scholar 

  • Liu K, Abrams SI . (2003b). Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-gamma. J Immunol 170: 6329–6337.

    CAS  PubMed  Google Scholar 

  • Liu K, Caldwell SA, Abrams SI . (2005a). Cooperative disengagement of Fas and intercellular adhesion molecule-1 function in neoplastic cells confers enhanced colonization efficiency. Cancer Res 65: 1045–1054.

    CAS  PubMed  Google Scholar 

  • Liu K, Caldwell SA, Abrams SI . (2005b). Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res 65: 4376–4388.

    CAS  PubMed  Google Scholar 

  • Liu K, Caldwell SA, Greeneltch KM, Yang D, Abrams SI . (2006). CTL adoptive immunotherapy concurrently mediates tumor regression and tumor escape. J Immunol 176: 3374–3382.

    CAS  PubMed  Google Scholar 

  • Liu K, McDuffie E, Abrams SI . (2003). Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. J Immunol 171: 4164–4174.

    CAS  PubMed  Google Scholar 

  • Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756–2761.

    CAS  PubMed  Google Scholar 

  • Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB et al. (2006). Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176: 3402–3409.

    CAS  PubMed  Google Scholar 

  • Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ et al. (2006). All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66: 9299–9307.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Nagaraj S, Gabrilovich DI . (2007). Myeloid-derived suppressor cells. Adv Exp Med Biol 601: 213–223.

    PubMed  Google Scholar 

  • Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291: 319–322.

    CAS  PubMed  Google Scholar 

  • Ochoa AC, Zea AH, Hernandez C, Rodriguez PC . (2007). Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13: 721s–726s.

    CAS  PubMed  Google Scholar 

  • Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H et al. (1999). Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96: 2233–2238.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N et al. (2005). Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11: 2947–2953.

    CAS  PubMed  Google Scholar 

  • Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F . (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457–2464.

    CAS  PubMed  Google Scholar 

  • Otten GR, Germain RN . (1991). Split anergy in a CD8+ T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 251: 1228–1231.

    CAS  PubMed  Google Scholar 

  • Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA et al. (2003). Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198: 569–580.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Owen-Schaub L, Chan H, Cusack JC, Roth J, Hill LL . (2000). Fas and Fas ligand interactions in malignant disease. Int J Oncol 17: 5–12.

    CAS  PubMed  Google Scholar 

  • Pardoll D . (2003). Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807–839.

    CAS  PubMed  Google Scholar 

  • Pawelec G, Ouyang Q, Colonna-Romano G, Candore G, Lio D, Caruso C . (2002). Is human immunosenescence clinically relevant? Looking for ‘immunological risk phenotypes’. Trends Immunol 23: 330–332.

    CAS  PubMed  Google Scholar 

  • Penn I . (1999). Posttransplant malignancies. Transplant Proc 31: 1260–1262.

    CAS  PubMed  Google Scholar 

  • Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372–8377.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Pollard JW . (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78.

    CAS  PubMed  Google Scholar 

  • Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C et al. (2006). A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12: 3381–3388.

    CAS  PubMed  Google Scholar 

  • Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB et al. (2005). Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931–939.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P et al. (2007). Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res 13: 4016–4025.

    CAS  PubMed  Google Scholar 

  • Sakaguchi S . (2004). Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531–562.

    CAS  PubMed  Google Scholar 

  • Schmielau J, Finn OJ . (2001). Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 61: 4756–4760.

    CAS  PubMed  Google Scholar 

  • Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I . (2004). High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64: 6337–6343.

    CAS  PubMed  Google Scholar 

  • Shevach EM . (2000). Regulatory T cells in autoimmmunity*. Annu Rev Immunol 18: 423–449.

    CAS  PubMed  Google Scholar 

  • Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H et al. (2003). B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849–861.

    CAS  PubMed  Google Scholar 

  • Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S . (2007). Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67: 4507–4513.

    CAS  PubMed  Google Scholar 

  • Smyth MJ, Dunn GP, Schreiber RD . (2006). Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90: 1–50.

    CAS  PubMed  Google Scholar 

  • Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA . (2000). Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192: 755–760.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Steinman RM, Hawiger D, Nussenzweig MC . (2003). Tolerogenic dendritic cells. Annu Rev Immunol 21: 685–711.

    CAS  PubMed  Google Scholar 

  • Stewart TJ, Greeneltch KM, Lutsiak ME, Abrams SI . (2007). Immunological responses can have both pro- and antitumour effects: implications for immunotherapy. Exp Rev Mol Med 9: 1–20.

    Google Scholar 

  • Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P et al. (2007). Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 67: 5454–5460.

    CAS  PubMed  Google Scholar 

  • Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM . (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11: 6713–6721.

    CAS  PubMed  Google Scholar 

  • Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S et al. (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7: 94–100.

    CAS  PubMed  Google Scholar 

  • Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD et al. (2000). NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1: 515–520.

    CAS  PubMed  Google Scholar 

  • Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD et al. (2003). Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198: 1741–1752.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Thomas DA, Massague J . (2005). TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369–380.

    CAS  PubMed  Google Scholar 

  • Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS et al. (2006). Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381–3385.

    CAS  PubMed  Google Scholar 

  • Vakkila J, Lotze MT . (2004). Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641–648.

    CAS  PubMed  Google Scholar 

  • van Elsas A, Hurwitz AA, Allison JP . (1999). Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355–366.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Vogelstein B, Kinzler KW . (2004). Cancer genes and the pathways they control. Nat Med 10: 789–799.

    CAS  PubMed  Google Scholar 

  • von Reyher U, Strater J, Kittstein W, Gschwendt M, Krammer PH, Moller P . (1998). Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58: 526–534.

    CAS  PubMed  Google Scholar 

  • Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10: 48–54.

    PubMed  Google Scholar 

  • Whiteside TL . (2006). Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3–15.

    CAS  PubMed  Google Scholar 

  • Willimsky G, Blankenstein T . (2005). Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437: 141–146.

    CAS  PubMed  Google Scholar 

  • Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al. (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766–4772.

    CAS  PubMed  Google Scholar 

  • Worth LL, Lafleur EA, Jia SF, Kleinerman ES . (2002). Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9: 823–827.

    CAS  PubMed  Google Scholar 

  • Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura T et al. (2007). Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res 67: 3301–3309.

    CAS  PubMed  Google Scholar 

  • Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409–421.

    CAS  PubMed  Google Scholar 

  • Yu H, Kortylewski M, Pardoll D . (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41–51.

    CAS  PubMed  Google Scholar 

  • Zamanakou M, Germenis AE, Karanikas V . (2007). Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 111: 69–75.

    CAS  PubMed  Google Scholar 

  • Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J et al. (2005). Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65: 3044–3048.

    CAS  PubMed  Google Scholar 

  • Zhou G, Drake CG, Levitsky HI . (2006). Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628–636.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S I Abrams.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stewart, T., Abrams, S. How tumours escape mass destruction. Oncogene 27, 5894–5903 (2008). https://doi.org/10.1038/onc.2008.268

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2008.268

Keywords

This article is cited by

Search

Quick links